PH12022550525A1 - Immunogenic compositions against enteric diseases and methods for its preparation thereof - Google Patents

Immunogenic compositions against enteric diseases and methods for its preparation thereof

Info

Publication number
PH12022550525A1
PH12022550525A1 PH1/2022/550525A PH12022550525A PH12022550525A1 PH 12022550525 A1 PH12022550525 A1 PH 12022550525A1 PH 12022550525 A PH12022550525 A PH 12022550525A PH 12022550525 A1 PH12022550525 A1 PH 12022550525A1
Authority
PH
Philippines
Prior art keywords
polysaccharide
typhi
methods
preparation
present disclosure
Prior art date
Application number
PH1/2022/550525A
Other languages
English (en)
Inventor
Dattatreya Sarma Annamraju
Nikhil Dattatray Avalaskar
Vishal Bharat Chavan
Rajeev Mhalasakant Dhere
Sunil Kumar Goel
Yogesh Tukaram Hundekari
Chandrashekhar Dwarkanath Kamat
Sambhaji Shankar Pisal
Anil Pirajirao Taklikar
Original Assignee
Serum Institute Of India Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Institute Of India Pvt Ltd filed Critical Serum Institute Of India Pvt Ltd
Publication of PH12022550525A1 publication Critical patent/PH12022550525A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0275Salmonella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH1/2022/550525A 2019-09-03 2020-09-02 Immunogenic compositions against enteric diseases and methods for its preparation thereof PH12022550525A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921035435 2019-09-03
PCT/IN2020/050763 WO2021044436A2 (en) 2019-09-03 2020-09-02 Immunogenic compositions against enteric diseases and methods for its preparation thereof

Publications (1)

Publication Number Publication Date
PH12022550525A1 true PH12022550525A1 (en) 2023-03-20

Family

ID=72659843

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2022/550525A PH12022550525A1 (en) 2019-09-03 2020-09-02 Immunogenic compositions against enteric diseases and methods for its preparation thereof

Country Status (23)

Country Link
US (2) US20230149524A1 (https=)
EP (2) EP4249061A3 (https=)
JP (2) JP7732974B2 (https=)
KR (2) KR20240155975A (https=)
CN (1) CN114728053A (https=)
AR (1) AR119884A1 (https=)
AU (1) AU2020343943A1 (https=)
BR (1) BR112022003892A2 (https=)
CA (1) CA3149972A1 (https=)
CO (1) CO2022003789A2 (https=)
CR (1) CR20220132A (https=)
EC (1) ECSP22031077A (https=)
GB (2) GB2603362B (https=)
GE (2) GEP20257808B (https=)
IL (1) IL291006B2 (https=)
JO (1) JOP20200214A1 (https=)
MA (1) MA56283A1 (https=)
MX (1) MX2022002693A (https=)
PE (1) PE20221442A1 (https=)
PH (1) PH12022550525A1 (https=)
PY (1) PY2051122A (https=)
WO (1) WO2021044436A2 (https=)
ZA (1) ZA202203368B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121569027A (zh) * 2023-07-21 2026-02-24 葛兰素史克生物有限公司 免疫原性组合物
WO2025217253A1 (en) * 2024-04-12 2025-10-16 Neogen Corporation Neutralizing compositions and related methods

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
AU1420897A (en) * 1996-12-18 1998-07-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Conjugate vaccine for (salmonella paratyphi) a
DE69941574D1 (de) 1998-08-19 2009-12-03 Baxter Healthcare Sa Immunogenes beta-propionamido-gebundenes polysaccharid-protein konjugat geeignet als impfstoff und hergestellt bei verwendung von n-acryloyliertem polysaccharid
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
PE20110072A1 (es) 2005-06-27 2011-02-04 Glaxosmithkline Biolog Sa Composicion inmunogenica
AU2007294731B2 (en) 2006-09-13 2014-04-17 Abbvie Inc. Cell culture improvements
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
FR2938265B1 (fr) 2008-11-12 2011-07-15 Univ Claude Bernard Lyon Procede pour le pilotage d'un traitement de depolymerisation par ultrasons d'un biopolymere hydrosoluble
CA2836153C (en) * 2009-12-17 2016-06-21 Fina Biosolutions, Llc Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
US9011871B2 (en) * 2011-11-07 2015-04-21 University Of Maryland, Baltimore Broad spectrum vaccine against typhoidal and non-typhoidal Salmonella disease
IN2012MU00206A (https=) * 2012-01-20 2013-08-09
MX354103B (es) 2012-01-30 2018-02-13 Serum Inst India Ltd Composicion inmunogenica.
CN102935226B (zh) * 2012-11-16 2014-01-22 罗益(无锡)生物制药有限公司 伤寒甲型副伤寒结合疫苗及其制备方法
KR102447303B1 (ko) * 2013-08-24 2022-09-23 브하라트 바이오테크 인터내셔날 리미티드 박테리아성 백신 및 그의 제조방법
CN104383532A (zh) * 2014-12-02 2015-03-04 云南沃森生物技术股份有限公司 一种用乙肝表面抗原为载体蛋白的细菌多糖蛋白结合物疫苗及其制备方法
CN104587461A (zh) * 2015-01-05 2015-05-06 云南沃森生物技术股份有限公司 伤寒、甲型乙型副伤寒多糖蛋白结合型多价联合疫苗
WO2017006349A1 (en) * 2015-07-04 2017-01-12 Bharat Biotech International Limited Polysaccharide vaccine formulations and processes for industrial production of bacterial polysaccharides
US20190134177A1 (en) * 2016-04-25 2019-05-09 National Institute Of Immunology Conjugate for vaccination against typhoid comprising chemical conjugate of vi polysaccharide and flagellin, a process for producing the same and a composition comprising the conjugate
MY191163A (en) 2016-08-26 2022-06-03 The Centers For Disease Control And Prevention Cdc Multivalent vaccine composition
US11739356B2 (en) * 2017-05-05 2023-08-29 Serum Institute Of India Private Limited Method for removal of impurities from bacterial capsular polysaccharide based preparations
CN111032078A (zh) 2017-07-18 2020-04-17 血清研究所印度私人有限公司 具有改善的稳定性、增强的免疫原性和降低的反应原性的免疫原性组合物及其制备方法
EA202190778A1 (ru) 2018-10-12 2021-08-05 Серум Инститьют Оф Индия Прайват Лтд Композиция комбинированной вакцины, содержащая уменьшенную дозу инактивированного полиовируса, и способ её получения
MX2021005500A (es) * 2018-11-10 2021-09-08 Bharat Biotech Int Ltd Composiciones inmunogenicas de glicoconjugados multivalentes.

Also Published As

Publication number Publication date
US20230149524A1 (en) 2023-05-18
IL291006A (en) 2022-05-01
JP2024178271A (ja) 2024-12-24
AU2020343943A1 (en) 2022-03-24
CA3149972A1 (en) 2021-03-11
KR20240155975A (ko) 2024-10-29
GEAP202515919A (en) 2025-05-27
JOP20200214A1 (ar) 2021-03-03
PY2051122A (es) 2021-08-11
EP4249061A3 (en) 2023-11-15
EP4025246A2 (en) 2022-07-13
PE20221442A1 (es) 2022-09-21
CR20220132A (es) 2022-05-06
IL291006B2 (en) 2026-03-01
WO2021044436A3 (en) 2021-05-27
MX2022002693A (es) 2022-07-12
GB202204276D0 (en) 2022-05-11
JP7732974B2 (ja) 2025-09-02
GB2629746B (en) 2025-01-29
GB2603362A (en) 2022-08-03
IL291006B1 (en) 2025-11-01
GEP20257808B (en) 2025-10-27
US20250134980A1 (en) 2025-05-01
ZA202203368B (en) 2022-05-25
GB2629746A (en) 2024-11-06
WO2021044436A2 (en) 2021-03-11
BR112022003892A2 (pt) 2022-05-24
KR20220087437A (ko) 2022-06-24
GB2603362B (en) 2025-01-15
ECSP22031077A (es) 2022-05-31
AR119884A1 (es) 2022-01-19
CN114728053A (zh) 2022-07-08
JP2022546763A (ja) 2022-11-08
CO2022003789A2 (es) 2022-04-19
MA56283A1 (fr) 2023-01-31
EP4249061A2 (en) 2023-09-27

Similar Documents

Publication Publication Date Title
PH12020550891A1 (en) Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
PH12021551448A1 (en) Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
JP2004512269A5 (https=)
MY182282A (en) Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
RU2012138368A (ru) 15-валентная вакцинная композиция на основе конъюгата пневмококкового полисахарида с белком
WO2010141312A3 (en) Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
PH12022550525A1 (en) Immunogenic compositions against enteric diseases and methods for its preparation thereof
JP2020114838A (ja) 百日咳菌免疫原性ワクチン組成物
Bansal et al. Genetic engineering of Salmonella spp. for novel vaccine strategies and therapeutics
WO2010083477A3 (en) Broad spectrum vaccine against non-typhoidal salmonella
RU2013145547A (ru) Адъювант на основе низкомолекулярного пептидогликана клеточной стенки бактерий
US20210401960A1 (en) Multivalent glycoconjugates immunogenic compositions
Donachie Vaccine development against Pasteurella haemolytica infections in sheep
MX2023005221A (es) Composiciones inmunogenicas para uso en vacunas neumococicas.
ZA202402956B (en) Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof
Beuvery Immunisation against bacterial meningitis
Rivera-Patron et al. Quillaja brasiliensis leaf saponins and their nanoparticles are strong inducers of early immune responses
MX2015017677A (es) Vacuna multivalente que contiene porinas de s. typhi y s. typhimurium contra fiebre tifoidea, paratifoidea y salmonelosis no tifoideas.
Underdown et al. Parenteral immunization and protection from mucosal infection
MX2025005300A (es) Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos
Czerkinsky Physical and Chemical Characterization and Immunologic Properties of Salmonella enterica Serovar Typhi Capsular Polysaccharide-Diphtheria Toxoid Conjugates
Haldar Designing broad-specificity, multi-subunit vaccines against enteric infections and studies on their immunogenicity and protective efficacy in animal models
EA202191647A1 (ru) Композиции, содержащие конъюгаты полисахарида из streptococcus pneumoniae и белка, и способы их применения
Szu et al. Escherichia coli O157
MX2025011233A (es) Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y usos de estos